| Today’s Big NewsMar 13, 2024 |
|
March 18-20, 2024 | Savannah, GA
The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer.
Secure 50% off Your Fierce TMF Summit Pass | LIMITED Passes Available: Use Promo Code LASTCHANCE.
Secure your spot Today!
 |
|
| By Annalee Armstrong With the FDA due to announce the approval of the first drug for metabolic dysfunction-associated steatohepatitis (MASH), Ionis Pharmaceuticals is raising its hand to showcase a phase 2 asset that has improved symptoms of the liver disease. |
|
|
|
By Max Bayer Mindstate Design Labs' lead AI-derived psychedelic is headed for the clinic after the biotech filed an IND with the FDA. The former Y Combinator company is still chugging off an $11.5 million seed round but is now considering next financing plans. |
By Max Bayer In 2022, the highest-paid R&D executive made $12.2 million. John Reed, M.D., Ph.D., of Johnson & Johnson is telling the rest of the field to hold his beaker. |
By Gabrielle Masson Sanofi will be closing the doors to a U.K. research facility, a move that will impact around 90 people, a spokesperson told Fierce Biotech. |
|
Protect performance with a high-purity RNase Inhibitor that preserves RNA at elevated temperatures. Maintain accurate transcript abundance with a high-efficiency, low-bias cDNA amplification polymerase. 
|
|
By Annalee Armstrong With 99% of patients experiencing an adverse event, the FDA is skeptical that the risks associated with Geron’s myelodysplastic syndromes medicine imetelstat outweigh the potential benefit of treatment, particularly in patients with lower-risk cases of the blood cancer. |
By Nick Paul Taylor Novartis is stepping on the cGAS. Three years after securing an option on an IFM Therapeutics subsidiary, the Swiss drugmaker has pulled the trigger on the deal and paid $90 million upfront for small molecules that inhibit the cGAS-STING pathway. |
By James Waldron Silence Therapeutics used its full-year earnings results this morning to unveil a phase 2 win—but also the loss of one of its partnerships. |
By James Waldron As Crinetics prepares to make a tilt for FDA approval in a rare growth disorder later this year, a topline readout from a phase 2 study suggests the same drug also has potential to treat symptoms associated with a neuroendocrine tumor. |
By James Waldron Almirall is handing over $3 million for Eloxx Pharmaceuticals’ molecule aimed at a pair of rare skin diseases and potentially more just before the drug enters the clinic. |
By Fraiser Kansteiner After Takeda’s unsuccessful attempt to sell an Austrian manufacturing and development site, the Japan-based company is calling it quits on much of the operations at the facility. Nearly 200 employees are set to lose their jobs as part of the move. |
By Helen Floersh Fortrea is offloading its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners, a private equity firm, for up to $345 million. |
By Conor Hale Once slated to either strike out on their own or be the subject of a potential sale, Medtronic’s patient monitoring and respiratory intervention divisions will see new life after merging into a single multibillion-dollar arm dubbed Acute Care and Monitoring. Fierce Medtech spoke with the unit's president, Frank Chan, about where the division is headed. |
By Heather Landi How will the conversations about AI in healthcare change by next year's HIMSS conference? Hackensack Meridian CEO Robert Garrett predicts that pilot projects underway now will roll out into practice. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," join Conor Hale, Senior Editor of Fierce Medtech, and Andrea Park, Deputy Editor of Fierce Life Sciences, as they share the highlights of this year's Fierce Medtech Fierce 15. |
|
|---|
|
|
Whitepaper Explore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
